Trial Profile
A Phase 1 Ascending Dose And Parallel Group Trial To Establish The Safety, Tolerability AND Pharmacokinetic Profile Of Multiple Intravitreous Injections Of ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Multiple Doses Of Lucentis® 0.5 mg/Eye, Or With One Induction Dose Of Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Jul 2019
Price :
$35
*
At a glance
- Drugs Avacincaptad pegol (Primary) ; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors IVERIC bio
- 25 Apr 2014 New trial record